Kymriah involves white blood cells of patients being genetically modified so that they recognise and attack cancer cells
Keystone
Basel-based pharmaceutical company Novartis has received approval for its personalised cell therapy Kymriah in Switzerland. Children and adults who suffer from certain types of blood cancer will be able to undergo the one-time treatment, which is set to cost CHF370,000 ($371,000).
Kymriah is already registered in the US, the EU and other countries. In the US, the treatment costs $475,000; the EU has said it will work with health officials to find fair, value-based pricing.
As in the US, pricing in Switzerland is set to be linked to the success of the therapy, although the details were still being worked out, said Kay Moeller-Heske, head of oncology at Novartis Switzerland, on Monday. The drug is not covered by obligatory health insurance, he added.
Kymriah involves white blood cells of patients being genetically modified so that they recognise and attack cancer cells. Novartis is the first Swiss pharmaceutical company to be approved for such therapy.
The number of possible treatment centres in Switzerland would initially be very limited as the Kymriah cell therapy places high demands on the production facilities and the staff, according to Moeller-Heske.
He pointed out, however, that the number of patients was expected to be very low at first: a “low two-digit number” of patients, with four or five being children.
What is Kymriah and what does it do?
Kymriah, formerly known as CTL019, is a type of immunotherapyExternal link known as a chimeric antigen receptor T cell (CAR-T) therapy, and is first of its kind to receive FDA approval. Kymriah is intended for use in patients with a specific type of childhood leukaemia known as ALLExternal link. It is a one-time treatment that involves modifying a patient’s own T-cells – a type of white blood cell – and then using them to target and destroy cancer cells. Until now, ALL has had a very poor survival rate – fewer than 10% of patients survive five yearsExternal link.
More
More
Will exclusive collaborations yield more drug breakthroughs?
This content was published on
Recently FDA-approved, Novartis’s pioneering immunotherapy was developed through an agreement with University of Pennsylvania researchers.
‘Dr Pump’ sentenced for administering unauthorised substances
This content was published on
A Bern Regional Court has found the Solothurn doctor known as "Dr Pump" guilty of offences against the Sports Promotion Law. The man had administered unauthorised substances to patients.
This content was published on
Volunteering can have a positive effect on mental health. According to a survey conducted in Switzerland, Germany and Austria, people who volunteer for others also strengthen themselves.
This content was published on
Twint is being used more and more frequently to make purchases at the till or transfer money to friends using a smartphone. By the middle of the year, the payment app already had more than six million users in Switzerland.
This content was published on
The meeting between Ukrainian President Volodymyr Zelensky and Russian President Vladimir Putin should take place in Europe, according to French President Emmanuel Macron. He is calling for it to be held in Geneva.
This content was published on
Zug-based mining and commodities trading giant Glencore plans to inject more than a dozen billion dollars into the expansion of two Argentine copper production sites.
Polish climber dies near Zermatt after falling into crevasse
This content was published on
A Polish mountaineer died on Sunday after falling into a crevasse on the Monte Rosa glacier in the Swiss resort of Zermatt.
This content was published on
Production in Switzerland's secondary sector fell in the second quarter of 2025. The decline was more pronounced in the construction sector than for industry.
Swiss army recruits remain in hospital after gruelling test exercise
This content was published on
Four potential recruits for the elite Swiss grenadier unit were hospitalised last week after taking part in a gruelling exercise in hot weather. Three remain in hospital with one placed temporarily in an artificial coma.
University of Basel to mark 125th anniversary of Nietzsche’s death
This content was published on
This month the University of Basel is celebrating the German philosopher Friedrich Nietzsche, who was a professor there from 1869 to 1879. August 25th marks the 125th anniversary of his death.
Trump tariffs: Swiss brands struggle to adapt to 39% tariff
This content was published on
Swiss brands like Victorinox, the manufacturer of the iconic pocket knife, are struggling to adapt to the 39% tariff imposed by the United States on imports of Swiss goods.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis’s new $475,000 cancer drug among most expensive ever
This content was published on
Bruno Strigini, chief executive of oncology at Novartis, said: “We carefully considered the appropriate price and looked at many factors, including the medical and clinical value.” He was speaking on Wednesday shortly after the treatment was approved by the US Food and Drug Administration (FDA), which gave Novartis a green light to use the medicine…
This content was published on
The increases are primarily due to demographic changes. There are increasing numbers of old people in the population, and old people tend to have more chronic diseases, said Pascale Strupler, director of the Swiss Federal Office of Public Health, at a press conference on Monday. The good news: the risk of dying from cancer decreased…
Study finds increased paediatric cancer risk near motorways
This content was published on
Researchers from the Institute for Social and Preventive Medicine (ISPM) looked for relationships between proximity to a Swiss motorway and the number of cancer cases registered in children between 1985 and 2008. They found that children growing up within 100 metres of a motorway had a 47% to 57% higher risk of contracting leukaemia. Despite…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.